X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
plx4032 (103) 103
index medicus (78) 78
humans (75) 75
melanoma (72) 72
oncology (53) 53
braf (49) 49
mutation (45) 45
proto-oncogene proteins b-raf - genetics (44) 44
vemurafenib (44) 44
cancer (42) 42
metastatic melanoma (38) 38
melanoma - drug therapy (37) 37
proto-oncogene proteins b-raf - antagonists & inhibitors (33) 33
mutations (30) 30
cell line, tumor (29) 29
indoles - pharmacology (29) 29
sulfonamides - pharmacology (29) 29
melanoma - genetics (28) 28
melanoma - pathology (26) 26
indoles - therapeutic use (25) 25
resistance (25) 25
sulfonamides - therapeutic use (25) 25
pathway (22) 22
b-raf (20) 20
female (19) 19
animals (18) 18
kinase (18) 18
protein kinase inhibitors - pharmacology (18) 18
acquired-resistance (17) 17
article (17) 17
male (17) 17
proto-oncogene proteins b-raf - metabolism (17) 17
survival (17) 17
therapy (17) 17
drug therapy (16) 16
skin neoplasms - drug therapy (16) 16
antineoplastic agents - pharmacology (15) 15
inhibitor (15) 15
skin neoplasms - pathology (15) 15
adult (14) 14
dermatology (14) 14
malignant-melanoma (14) 14
proliferation (14) 14
skin neoplasms - genetics (14) 14
activation (13) 13
antineoplastic agents - therapeutic use (13) 13
gene mutations (13) 13
middle aged (13) 13
aged (12) 12
care and treatment (12) 12
cell proliferation - drug effects (12) 12
kinases (12) 12
mek (12) 12
melanoma - enzymology (12) 12
melanoma - metabolism (12) 12
neoplasms (12) 12
pharmacology & pharmacy (12) 12
braf inhibitor (11) 11
cell biology (11) 11
cells (11) 11
drug resistance, neoplasm (11) 11
genetic aspects (11) 11
phosphorylation (11) 11
raf (11) 11
apoptosis (10) 10
growth (10) 10
metastasis (10) 10
mice (10) 10
protein kinase inhibitors - therapeutic use (10) 10
sorafenib (10) 10
erk (9) 9
inhibition (9) 9
proteins (9) 9
research (9) 9
signal transduction (9) 9
signal transduction - drug effects (9) 9
skin cancer (9) 9
targeted therapy (9) 9
apoptosis - drug effects (8) 8
biochemistry & molecular biology (8) 8
cutaneous melanoma (8) 8
drug resistance (8) 8
drug resistance, neoplasm - drug effects (8) 8
health aspects (8) 8
map kinase signaling system - drug effects (8) 8
mutation - genetics (8) 8
neoplasm metastasis (8) 8
plx4720 (8) 8
raf inhibitors (8) 8
tumors (8) 8
aged, 80 and over (7) 7
analysis (7) 7
cell lines (7) 7
cell proliferation (7) 7
dabrafenib (7) 7
rg7204 (7) 7
sensitivity (7) 7
braf inhibitors (6) 6
braf mutation (6) 6
development and progression (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 14, pp. 1628 - 1634
Journal Article
MEDICINE, ISSN 0025-7974, 12/2017, Volume 96, Issue 48, pp. e8404 - e8404
To compare BRAF V600E status of primary melanoma and brain metastases to assess for discordance by cross-sectional study, and to evaluate clinical implications... 
SURVIVAL | proto-oncogene proteins B-raf | PLX4032 | brain metastases | STAGE | brain neoplasm | KINASE | vemurafenib | BRAF inhibitor | melanoma | PROLIFERATION | CANCER | MEDICINE, GENERAL & INTERNAL | dabrafenib | Index Medicus | Abridged Index Medicus
Journal Article
Future Oncology, ISSN 1479-6694, 05/2012, Volume 8, Issue 5, pp. 509 - 523
Vemurafenib is a potent inhibitor of the mutated BRAF kinase. Phase I and II CIinical trials of vemurafenib showed response rates of more than 50% in patients... 
zelboraf | metastatic | PLX4032 | vemurafenib | melanoma | BRAF | RG7204 | SURVIVAL | CELLS | ACTIVATION | vemurafenib zelboraf | DRUG-RESISTANCE | CANCER | PLX4032 RG7204 | melanoma metastatic | METASTATIC MELANOMA | ONCOLOGY | PATHWAY | GROWTH | B-RAF | MUTATIONS
Journal Article
ONCOGENESIS, ISSN 2157-9024, 09/2018, Volume 7
Approximately half of all melanoma patients harbour activating mutations in the serine/threonine kinase BRAF. This is the basis for one of the main treatment... 
POTENT ANTITUMOR-ACTIVITY | THERAPY | PLX4032 | ONCOLOGY | GROWTH | ACQUIRED-RESISTANCE | RAF INHIBITORS | KAPPA-B | RECEPTORS | UP-REGULATION | MAPK PATHWAY
Journal Article
Cancer Letters, ISSN 0304-3835, 10/2018, Volume 433, pp. 147 - 155
Journal Article
Journal Article
Journal Article
Journal Article
BMC CANCER, ISSN 1471-2407, 09/2014, Volume 14
Background: Mutations in the activation segment of the v-raf murine sarcoma viral oncogene homolog B (BRAF) gene are present in approximately 50% of melanomas.... 
SURVIVAL | Crystal structures | Metastatic melanoma | Monoallelic mutation | PLX4032 | BRAF inhibitor | MALIGNANT-MELANOMA | CANCER | BRAF(V600E) | V600E | V600DK601del | Vemurafenib | POTENT | ONCOLOGY | BRAF MUTATIONS | Rare BRAF mutations | INHIBITOR
Journal Article
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ISSN 0006-291X, 01/2011, Volume 404, Issue 4, pp. 958 - 962
Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mutant kinase BRAF(V600E), as a result of the BRAF(T1799A) mutation, plays a... 
BASES | PLX4032 | BIOCHEMISTRY & MOLECULAR BIOLOGY | KINASE | BRAF inhibitor | PATHOGENIC ROLE | BRAF mutation | Genetic-dependent therapy | Thyroid cancer | BIOPHYSICS | CLINICAL-IMPLICATIONS | RAF INHIBITORS | RG7204 | MUTANTS | INHIBITION | THERAPY | PHOSPHORYLATION | SENSITIVITY | THYROID | CELL PROLIFERATION | MELANOMAS | MUTATIONS | 60 APPLIED LIFE SCIENCES
Journal Article
Journal Article
Journal Article